InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: None

Thursday, 04/28/2022 11:38:48 AM

Thursday, April 28, 2022 11:38:48 AM

Post# of 42749
The wait for data is brutal. But it will be worth it. The primary endpoint population of the ACTIV trial had 243% efficacy in the LIVE-AIR trial. No other Covid treatment at any stage comes close to that efficacy. And there is still no good treatment for newly hospitalized patients which is obviously a very important stage to treat. Lenzilumab is coming soon to a hospital near you.